Which has stronger earnings & valuation, EXEL or ALMS?

Exelixis has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.56 $782.57M $3.18 16.14 Alumis $24.05M 134.49 -$243.32M -$1.98 N/A

Is EXEL or ALMS more profitable?

Exelixis has a net margin of 35.33% compared to Alumis' net margin of -2,825.70%. Exelixis' return on equity of 42.17% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Alumis -2,825.70% -88.79% -70.72%

Does the media favor EXEL or ALMS?

In the previous week, Exelixis had 21 more articles in the media than Alumis. MarketBeat recorded 43 mentions for Exelixis and 22 mentions for Alumis. Alumis' average media sentiment score of 0.36 beat Exelixis' score of 0.24 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Alumis 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALMS or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than Alumis. MarketBeat recorded 29 mentions for Arrowhead Pharmaceuticals and 22 mentions for Alumis. Alumis' average media sentiment score of 0.36 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to BMRN or ALMS?

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than Alumis. MarketBeat recorded 32 mentions for BioMarin Pharmaceutical and 22 mentions for Alumis. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Alumis' score of 0.36 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 9 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MDGL or ALMS?

In the previous week, Alumis had 13 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 22 mentions for Alumis and 9 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.52 beat Alumis' score of 0.36 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ALMS or ABVX?

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 134.49 -$243.32M -$1.98 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ALMS or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Abivax N/A -99.02% -70.26%

Does the media refer more to ALMS or ABVX?

In the previous week, Alumis had 20 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Alumis and 2 mentions for Abivax. Abivax's average media sentiment score of 1.81 beat Alumis' score of 0.36 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alumis (ALMS) Competitors

$25.37 -2.16 (-7.85%)

Closing price 04:00 PM Eastern

Extended Trading

$25.37 0.00 (0.00%)

As of 05:15 PM Eastern

Compare

ALMS vs. EXEL, ARWR, BMRN, MDGL, and ABVX

Should you buy Alumis stock or one of its competitors? Alumis's main competitors and comparable companies include Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alumis compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Exelixis has a net margin of 35.33% compared to Alumis' net margin of -2,825.70%. Exelixis' return on equity of 42.17% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Alumis	-2,825.70%	-88.79%	-70.72%

Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Alumis has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exelixis has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.56	$782.57M	$3.18	16.14
Alumis	$24.05M	134.49	-$243.32M	-$1.98	N/A

In the previous week, Exelixis had 21 more articles in the media than Alumis. MarketBeat recorded 43 mentions for Exelixis and 22 mentions for Alumis. Alumis' average media sentiment score of 0.36 beat Exelixis' score of 0.24 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alumis	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis presently has a consensus target price of $49.79, suggesting a potential downside of 3.01%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 58.85%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Exelixis beats Alumis on 10 of the 17 factors compared between the two stocks.

How does Alumis compare to Arrowhead Pharmaceuticals?

Alumis (NASDAQ:ALMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than Alumis. MarketBeat recorded 29 mentions for Arrowhead Pharmaceuticals and 22 mentions for Alumis. Alumis' average media sentiment score of 0.36 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Alumis. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	134.49	-$243.32M	-$1.98	N/A
Arrowhead Pharmaceuticals	$829.45M	15.16	-$1.63M	-$2.25	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Alumis' net margin of -2,825.70%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Alumis has a beta of -0.69, meaning that its share price is 169% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Alumis presently has a consensus target price of $40.30, indicating a potential upside of 58.85%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 9.07%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Alumis and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Alumis compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than Alumis. MarketBeat recorded 32 mentions for BioMarin Pharmaceutical and 22 mentions for Alumis. BioMarin Pharmaceutical's average media sentiment score of 0.67 beat Alumis' score of 0.36 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	9 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioMarin Pharmaceutical presently has a consensus price target of $88.00, indicating a potential upside of 26.53%. Alumis has a consensus price target of $40.30, indicating a potential upside of 58.85%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

BioMarin Pharmaceutical has a net margin of 2.14% compared to Alumis' net margin of -2,825.70%. BioMarin Pharmaceutical's return on equity of 5.32% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Alumis	-2,825.70%	-88.79%	-70.72%

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Alumis has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.18	$348.90M	$0.37	187.97
Alumis	$24.05M	134.49	-$243.32M	-$1.98	N/A

Summary

BioMarin Pharmaceutical beats Alumis on 12 of the 16 factors compared between the two stocks.

How does Alumis compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Alumis has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.90	-$288.28M	-$12.89	N/A
Alumis	$24.05M	134.49	-$243.32M	-$1.98	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Alumis' net margin of -2,825.70%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Alumis	-2,825.70%	-88.79%	-70.72%

Madrigal Pharmaceuticals presently has a consensus target price of $689.93, suggesting a potential upside of 28.89%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 58.85%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alumis had 13 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 22 mentions for Alumis and 9 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.52 beat Alumis' score of 0.36 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market. Comparatively, Alumis has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market.

Summary

Alumis beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alumis compare to Abivax?

Alumis (NASDAQ:ALMS) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	134.49	-$243.32M	-$1.98	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Alumis had 20 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Alumis and 2 mentions for Abivax. Abivax's average media sentiment score of 1.81 beat Alumis' score of 0.36 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alumis has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Alumis currently has a consensus target price of $40.30, suggesting a potential upside of 58.85%. Abivax has a consensus target price of $156.50, suggesting a potential upside of 23.41%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

47.9% of Abivax shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Abivax	N/A	-99.02%	-70.26%

Summary

Alumis beats Abivax on 10 of the 16 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.23B	$3.71B	$6.99B	$12.83B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-12.81	9.18	268.64	24.76
Price / Sales	134.49	1,258.18	585.26	96.30
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	8.81	17.94	11.31	6.45
Net Income	-$243.32M	-$13.23M	$3.44B	$347.05M
7 Day Performance	-6.45%	3.74%	2.25%	0.98%
1 Month Performance	-10.39%	-1.17%	-0.25%	-0.64%
1 Year Performance	484.56%	62.22%	76.14%	22.27%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.8556 of 5 stars	$25.37 -7.8%	$40.30 +58.8%	+540.2%	$3.23B	$24.05M	N/A	N/A	News Coverage Upcoming Earnings
EXEL Exelixis	2.2244 of 5 stars	$53.03 -5.3%	$49.29 -7.1%	+40.4%	$14.07B	$2.32B	17.62	1,077	Earnings Report Analyst Downgrade
ARWR Arrowhead Pharmaceuticals	1.9566 of 5 stars	$84.65 -3.1%	$96.92 +14.5%	+437.9%	$12.30B	$622.01M	N/A	400	Earnings Report Analyst Revision
BMRN BioMarin Pharmaceutical	4.5144 of 5 stars	$60.02 -0.9%	$88.26 +47.1%	+20.1%	$11.71B	$3.22B	43.81	3,221	Earnings Report Analyst Upgrade
MDGL Madrigal Pharmaceuticals	4.0213 of 5 stars	$467.32 -5.2%	$688.20 +47.3%	+49.1%	$11.37B	$958.40M	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. EXEL, ARWR, BMRN, MDGL, and ABVX

How does Alumis compare to Exelixis?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Summary

How does Alumis compare to BioMarin Pharmaceutical?

Summary

How does Alumis compare to Madrigal Pharmaceuticals?

Summary

How does Alumis compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. EXEL, ARWR, BMRN, MDGL, and ABVX

How does Alumis compare to Exelixis?

Is EXEL or ALMS more profitable?

Which has more volatility and risk, EXEL or ALMS?

Do institutionals & insiders have more ownership in EXEL or ALMS?

Which has stronger earnings & valuation, EXEL or ALMS?

Does the media favor EXEL or ALMS?

Do analysts rate EXEL or ALMS?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Does the media refer more to ALMS or ARWR?

Do institutionals and insiders believe in ALMS or ARWR?

Which has higher earnings and valuation, ALMS or ARWR?

Is ALMS or ARWR more profitable?

Which has more volatility and risk, ALMS or ARWR?

Do analysts prefer ALMS or ARWR?

Summary

How does Alumis compare to BioMarin Pharmaceutical?

Does the media refer more to BMRN or ALMS?

Do institutionals & insiders believe in BMRN or ALMS?

Do analysts recommend BMRN or ALMS?

Is BMRN or ALMS more profitable?

Which has more volatility and risk, BMRN or ALMS?

Which has preferable valuation & earnings, BMRN or ALMS?

Summary

How does Alumis compare to Madrigal Pharmaceuticals?

Which has higher earnings and valuation, MDGL or ALMS?

Is MDGL or ALMS more profitable?

Do analysts recommend MDGL or ALMS?

Do institutionals and insiders hold more shares of MDGL or ALMS?

Does the media favor MDGL or ALMS?

Which has more risk & volatility, MDGL or ALMS?

Summary

How does Alumis compare to Abivax?

Which has better earnings and valuation, ALMS or ABVX?

Does the media refer more to ALMS or ABVX?

Which has more volatility & risk, ALMS or ABVX?

Do analysts rate ALMS or ABVX?

Do insiders & institutionals hold more shares of ALMS or ABVX?

Is ALMS or ABVX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools